Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2006-03-28
2006-03-28
Price, Elvis O. (Department: 1621)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S476000, C514S478000, C514S479000, C514S506000, C514S507000, C514S512000, C514S513000, C514S520000, C514S521000, C514S526000, C514S527000, C514S530000, C514S531000, C514S534000, C514S553000, C514S554000, C514S576000, C514S578000, C514S693000, C514S702000, C514S704000, C514S705000
Reexamination Certificate
active
07019031
ABSTRACT:
Oncoproteins such as Ras and RhoB are known to induce cell division in an unrestrained manner when such proteins are localized at the inner surface of a cancer cell membrane. The localization is effected by the prenylation reaction, whereby a hydrophobic group (e.g. a farnesyl group) is attached to the protein in the presence of an enzyme (e.g. farnesyl protein transferase). Deactivation of the prenylation enzyme through covalent modification can therefore ultimately result in the mitigation and/or cessation of cancer cell growth. Various prenylation inhibitors having the necessary structural groups to bond covalently, or essentially irreversibly, to the prenylation enzyme include carbonyl or thiocarbonyl compounds (or masked versions of these compounds) and alpha oxo-epoxides bonded to a hydrophobic, substrate-mimicking group. The carbonyl or thiocarbonyl compounds also contain a nucleofugal atom or group to enhance the tendency to form covalent bonds.
REFERENCES:
patent: 4235923 (1980-11-01), Durham
patent: 4900749 (1990-02-01), Matsumoto et al.
patent: 5733911 (1998-03-01), Eilon et al.
patent: 6166074 (2000-12-01), Pettersen et al.
patent: 0 147 217 (1985-07-01), None
patent: 0 170 048 (1986-02-01), None
patent: 0 248 597 (1987-12-01), None
patent: 0 335 315 (1989-10-01), None
patent: 0 410 244 (1991-01-01), None
patent: 0 534 546 (1993-03-01), None
patent: 0 752 465 (1997-01-01), None
patent: 1 599 532 (1981-10-01), None
patent: 07002821 (1995-01-01), None
patent: WO 91/15473 (1991-10-01), None
patent: WO 93/22304 (1993-11-01), None
patent: WO 00/04032 (2000-01-01), None
patent: WO 00/33826 (2000-06-01), None
Karl J. Okolotowicz, Wei-Jen Lee, Rosemarie F. Hartman, Scott R. Lefler, and Seth D. Rose,Inactivation of Protein Farnesyltransferase by Active-Site-Targeted Dicarbonyl Compounds, Arch. Pharm. Pharm. Med. Chem. 334, 194-202, 9 pages, 2001.
Journal of the Chemical Society,The Oxidation of αβ-Unsaturated Ketones with Alkaline Hydrogen Peroxide, pp. 665-670. 1949.
Journal of the American Chemical Society,Epoxidation of Alkenes with Bicarbonate-Activated Hydrogen Peroxide, vol. 122, pp. 3220-3221, 2000.
Tetrahedron,Enhanced disatereoselectivity in the addition of ester enolate to optically active α,β-epoxyaldehydes obtained from nerol and geraniol, vol. 52, No. 27, pp. 9047-9056, 1996.
Journal of the American Chemical Society,Catalytic Asymmetric Epoxidation and Kinetic Resolution: Modified Procedures Including in Situ Derivatization, vol. 109, pp. 5765-5780, 1987.
Hara, M. et al.,Identification of Ras Farnesylation Inhibitors by Microbial Screening, Proc. Natl. Acad. Sci, USA, vol. 90: 2281-2285 (1993).
Hartman Rosemarie F.
Kim Ann Y.
Lefler Scott R.
Okolotowicz Karl J.
Ottersberg Steven R.
Banner & Witcoff , Ltd.
Price Elvis O.
The Arizona Disease Control Research Commission
LandOfFree
Anticancer agents based on regulation of protein prenylation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer agents based on regulation of protein prenylation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer agents based on regulation of protein prenylation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3565827